Immunoglobulin therapy in recurrent pregnancy loss

ABSTRACT

Recurrent pregnancy loss is a global issue. This study was planned in order to evaluate the effects of high dose intravenous immunoglobulin [IVIg] in primary and secondary unexplained miscarriages in patients of recurrent pregnancy loss. Total 168 couples having history of primary or secondary recurrent pregnancy loss were included in the study. They were divided into IVIg group and control group. IVIg group was given 50 gm of IVIg on monthly basis. Control group was provided with normal saline drip at same intervals. Statistical package for social sciences 19 [SPSS 19] was used to analyze the data. Women receive IVIg treatment [primary + secondary recurrent pregnancy loss] shows significantly higher percentage of live birth as compare to control group [81%; p < 0.000]. Percentage of full term live birth is also significantly increased in IVIg group in comparison with control group [76.2%; p < 0.000]. In primary recurrent pregnancy loss total percentage of live births and full term live births were 85.3 and 79.4% in IVIg group while in control group it was 26.9% and 19.2% [p < 0.000]. In secondary recurrent pregnancy loss percentage of total number of live birth and full term live births in IVIg group is 78% and 74% in comparison with control group 32% and 26% respectively [p < 0.000]. High dose intravenous immunoglobulin has a beneficial role in patients of primary and secondary recurrent miscarriages